Related references
Note: Only part of the references are listed.Planning multi-arm screening studies within the context of a drug developmentprogram
James M. S. Wason et al.
STATISTICS IN MEDICINE (2013)
A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection
D. Magirr et al.
BIOMETRIKA (2012)
Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma
Lorenzo Trippa et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Toward a New Era in Cancer Treatment: Message from the New Editor-in-Chief
John C. Reed
MOLECULAR CANCER THERAPEUTICS (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Adaptive clinical trials in oncology
Donald A. Berry
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Optimal multistage designs for randomised clinical trials with continuous outcomes
James M. S. Wason et al.
STATISTICS IN MEDICINE (2012)
Optimal design of multi-arm multi-stage trials
James M. S. Wason et al.
STATISTICS IN MEDICINE (2012)
On the Usefulness of Outcome-Adaptive Randomization
Ying Yuan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Outcome-Adaptive Randomization: Is It Useful?
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Demystify Statistical Significance-Time to Move on From the P Value to Bayesian Analysis
J. Jack Lee
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim et al.
CANCER DISCOVERY (2011)
Bayesian adaptive randomization designs for targeted agent development
J. Jack Lee et al.
CLINICAL TRIALS (2010)
Personalized medicine in oncology: the future is now
Richard L. Schilsky
NATURE REVIEWS DRUG DISCOVERY (2010)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
Matthew R. Sydes et al.
TRIALS (2009)
Multi-arm clinical trials of new agents: Some design considerations
Boris Freidlin et al.
CLINICAL CANCER RESEARCH (2008)
Speeding up the evaluation of new agents in cancer
Mahesh K. B. Parmar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Should I stay or should I go? How the human brain manages the trade-off between exploitation and exploration
Jonathan D. Cohen et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2007)
Practical Bayesian adaptive randomisation in clinical trials
Peter F. Thall et al.
EUROPEAN JOURNAL OF CANCER (2007)
A randomly reinforced urn
P Muliere et al.
JOURNAL OF STATISTICAL PLANNING AND INFERENCE (2006)
Operational challenges in adaptive design implementation
P Gallo
PHARMACEUTICAL STATISTICS (2006)
The use of unequal randomisation ratios in clinical trials: A review
JC Dumville et al.
CONTEMPORARY CLINICAL TRIALS (2006)
Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer
P Royston et al.
STATISTICS IN MEDICINE (2003)
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
FJ Giles et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Stopping clinical trials because of treatment ineffectiveness:: a comparison of a futility design with a method of stochastic curtailment
J Whitehead et al.
STATISTICS IN MEDICINE (2003)
Estimation after adaptive allocation
VF Melfi et al.
JOURNAL OF STATISTICAL PLANNING AND INFERENCE (2000)